COVID-19 Funding Snapshot for Pharma Developers/Manufacturers

Views as of August 7, 2020

Pharma Developers/Manufacturers

COVID-19 pharmaceutical funding landscape

COVID-19 funding has predominantly

COVID-19 drug development

U.S. funding is spread across

government vaccine supply deals

Though funding appears

Select funding deals across

US public deals with disclosed

US public deals with disclosed

Ex-US public deals

with disclosed values

Foundation deals with disclosed

Industry deals with disclosed

COVID-19 funding deals disclaimer

Contributing authors:

Tony Stripling, Associate Consultant
Sean Saunders, Life Sciences Speciaist
Jennifer Henry, Associate Consultant
Patrick Marquet, Associate

Related Insights

Published Articles

Life Sciences & Pharma

The Growth of Radiotherapeutics: Addressing Supply Chain Complexity

May 21, 2025

Life Sciences & Pharma

Radiotherapeutics on the Rise: Cracking the Supply Chain Code

May 16, 2025

Life Sciences & Pharma

Unlocking Growth: Singapore's Role in Advancing Life Sciences and Medtech Innovations

March 10, 2025

Life Sciences & Pharma

Unlocking the Potential of Next-Generation PROTACs: A Strategic Roadmap for R&D Investment

March 7, 2025

Our client engaged L.E.K. Consulting to develop a market overview across multiple key therapeutic areas (e.g., oncology, immunology, neuroscience) and…

Life Sciences & Pharma

AI and Biopharma: New Solutions Emerging Across the US Value Chain

December 6, 2024

Executive Insights

Life Sciences & Pharma

In Need of an All-Inclusive Trip: Socio-Demographic Diversity in Psychedelic Research

November 15, 2024